As major U.S. retailers continue earnings season with their quarterly reports, Jim Cramer spotted some that managed to fend off the storm cloud that is e-commerce giant Amazon.
We're starting to see some chains that can actually compete, that can even win, in this difficult new environment," the "Mad Money" host said.Cramer earnings report results retailer sales second quarter store TJX Urban
Bristol-Myers Squibb (BMY) announced results for its combination treatment treating patients with metastatic renal cell carcinoma (kidney cancer). In the meantime, Bristol-Myers is still in good shape with respect to its Opdivo franchise.Bristol Myers cancer Myers Squibb Opdivo results sales stock study survival trial
AbbVie is on track to submit an NDA for elagolix in endometriosis before the end of Q3. The company has made considerable progress on all fronts over the last few months - Ingrezza is off to a strong start, partner AbbVie (NYSE:ABBV) is on track to submit an NDA for elagolix in endometriosis this quarter and to report phase 3 data in uterine fibroids in late 2017 or early 2018 while Asia partner Mitsubishi Tanabe (OTCPK:MTZPY) intends to start a Phase 3 trial of Ingrezza in Japan.AbbVie early elagolix Ingrezza Neurocrine Phase quarter results sales study
The Trade Desk, Inc. (NASDAQ: TTD) may not a household name among investors, but it has exhibited impressive results during its short stint as a public entity.
The Trade Desk went public in September 2016 at $28.75, 60% higher than its IPO price of $18.advertising growth investors market public quarter results Revenue stock Trade Desk
When Target Corp. (NYSE: TGT) reported its fiscal second-quarter financial results before the market opened on Wednesday, the retailer said that it had $1.23 in earnings per share (EPS) and $16.43 billion in revenue.
On the books, Target’s cash and cash equivalents totaled $2.29 billion at the end of the quarter, down from $2.51 billion at the end of the previous fiscal year.comparable consensus EPS fiscal quarter results Revenue sales second Wednesday
The quarterly results were not great but the company's BAMTech and streaming services announcement should be viewed as positive news.
The ESPN concerns have plagued this company for a while now and this was again the case when Disney reported its Q3 2017 financial results.Disney division investors operating reported results Revenue services streaming years
Shares of Agilent Technologies shot up more than 4 percent in extended trading after reporting its third-quarter fiscal year 2017 results after the bell.
Shares of Urban Outfitters skyrocketed more than 20 percent in after-hours trading.after earnings extended hours quarter report results second shares trading
As a value investor we are taught time and time again not to be obsessive over quarterly results and to take more of long term view on the company's prospects, but when a company you are invested in loses a quarter of its market cap in a single trading session, if you were not asking those difficult questions from your investment before, you sure are now. In the article that follows I show why I believe there is value in Office Depot (ODP) while it still trades at $2.2 billion market cap.business Depot market cap operating income results Retail Revenue Staples valuation YoY
Target Corp. (NYSE: TGT) is scheduled to release its fiscal second-quarter financial results before the markets open on Wednesday. Like many other companies in the retail sector, Target has been left bloody and battered, and with earnings approaching it seems like it’s only going to get worse.earnings EPS market Neutral perform quarter rating results sales store
Foamix Pharmaceuticals (FOMX) is a clinical stage pharmaceutical company focused on the development topical drugs for dermatological conditions. FOMX’s lead drug is FMX-101 — a topical formulation of the antibiotic minocycline — and is in Phase 3 development for the treatment of moderate-to-severe acne.drug endpoint FMX FOMX patients Phase results studies study trial
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) saw its shares sink to a 52-week low after the firm announced results from its midstage trial evaluating ZYN002 (cannabidiol [CBD] gel) for the treatment of knee pain due to osteoarthritis.
Excluding Monday’s move, Zynerba has underperformed the broad markets with the stock down 55% year to date.CBD osteoarthritis pain results shares treatment trial week ZYN002 Zynerba
If you are willing (and able) to look out to 2018 and beyond, there is a lot to like about this company.
The company has sold 161 out of the 216 total available units but management mentioned that the construction loan has already been paid off.debt estate expense project Q2 reported restrictions results XIN Xinyuan
The billionaire founder of Sun Pharmaceutical Industries Ltd. pledged that the drugmaker would do better after reporting its first loss in at least 12 years amid regulatory headaches and a weakening market for generic drugs.“The reason why we are suffering is our inability to execute,” Dilip Shanghvi said on a conference call with analysts after the results were released. Sun Pharma’s Israel-based unit Taro Pharmaceutical Industries Ltd. said it expects pricing pressure to continue.India’s pharma companies started reporting quarterly results two weeks ago, with many showing double-digit declines in revenue or profit.drug generic India Pharma pricing profit results Revenue Rs Sun
Recently, Galapagos (GLPG) announced positive results for its phase 2a trial treating patients with idiopathic pulmonary fibrosis (IPF). Not only was there a halt in disease progression, but Galapagos noted that its drug was the first of its class (autotaxin inhibitor) to have ever seen positive clinical data in patients with IPF.drug Galapagos GLPG1690 IPF market patients Phase placebo results trial
Reasons why this unloved and undervalued biotech stock should head substantially higher in the months ahead are provided below. Given that, the shares are clearly substantially undervalued given the likely approval of Azedra in early 2018.approval Azedra drug investors key Progenics results sales stock trial
I remarked early this year that Chesapeake (NYSE:CHK) is an outlier compared with its peers when it comes to its drilling strategy for this year, in that it does not intend to chase production growth. For the year so far, it achieved net operating profit of $547 million, meaning that the second quarter was better compared with the first despite the lower oil prices.Chesapeake debt longer oil operating quarter results Revenue Shale strategy